You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 20, 2025

TRAZODONE HYDROCHLORIDE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Trazodone Hydrochloride, and when can generic versions of Trazodone Hydrochloride launch?

Trazodone Hydrochloride is a drug marketed by Accord Hlthcare, Aiping Pharm Inc, Alvogen, Am Therap, Apotex, Apotex Inc, Aurobindo Pharma, Crossmedika Sa, Granules, Graviti Pharms, Natco, Norvium Bioscience, Oxford Pharms, Pliva, Quantum Pharmics, Rising, Sun Pharm Industries, Teva, Teva Pharms Usa, Torrent, Usl Pharma, Watson Labs, and Zydus Pharms. and is included in thirty-two NDAs.

The generic ingredient in TRAZODONE HYDROCHLORIDE is trazodone hydrochloride. There are fourteen drug master file entries for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the trazodone hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Trazodone Hydrochloride

A generic version of TRAZODONE HYDROCHLORIDE was approved as trazodone hydrochloride by APOTEX on March 25th, 1987.

  Try for Free

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for TRAZODONE HYDROCHLORIDE?
  • What are the global sales for TRAZODONE HYDROCHLORIDE?
  • What is Average Wholesale Price for TRAZODONE HYDROCHLORIDE?
Drug patent expirations by year for TRAZODONE HYDROCHLORIDE
Recent Clinical Trials for TRAZODONE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Simon Ducharme, MDPhase 3
Alzheimer's Drug Discovery FoundationPhase 3
University of New MexicoPhase 4

See all TRAZODONE HYDROCHLORIDE clinical trials

Pharmacology for TRAZODONE HYDROCHLORIDE
Medical Subject Heading (MeSH) Categories for TRAZODONE HYDROCHLORIDE
Anatomical Therapeutic Chemical (ATC) Classes for TRAZODONE HYDROCHLORIDE
Paragraph IV (Patent) Challenges for TRAZODONE HYDROCHLORIDE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
OLEPTRO Extended-release Tablets trazodone hydrochloride 150 mg and 300 mg 022411 1 2010-10-18

US Patents and Regulatory Information for TRAZODONE HYDROCHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sun Pharm Industries TRAZODONE HYDROCHLORIDE trazodone hydrochloride TABLET;ORAL 073137-002 Mar 24, 1993 AB RX No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Norvium Bioscience TRAZODONE HYDROCHLORIDE trazodone hydrochloride TABLET;ORAL 090514-001 Jun 2, 2009 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Torrent TRAZODONE HYDROCHLORIDE trazodone hydrochloride TABLET;ORAL 202180-003 Nov 27, 2013 AB RX No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Zydus Pharms TRAZODONE HYDROCHLORIDE trazodone hydrochloride TABLET;ORAL 205253-004 Oct 10, 2017 AB RX No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Teva Pharms Usa TRAZODONE HYDROCHLORIDE trazodone hydrochloride TABLET;ORAL 071523-001 Dec 11, 1987 AB RX No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Torrent TRAZODONE HYDROCHLORIDE trazodone hydrochloride TABLET;ORAL 202180-004 Nov 27, 2013 AB RX No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Market Dynamics and Financial Trajectory of Trazodone Hydrochloride

Last updated: July 4, 2025

Introduction

Trazodone hydrochloride, a widely prescribed antidepressant, has carved a significant niche in the pharmaceutical landscape since its approval by the U.S. Food and Drug Administration (FDA) in 1981. Originally developed by Mead Johnson Pharmaceuticals, this serotonin antagonist and reuptake inhibitor (SARI) treats major depressive disorder and finds off-label use for insomnia and anxiety. As global mental health challenges intensify, trazodone's role in addressing these issues underscores its enduring relevance. This analysis delves into the drug's market dynamics—encompassing supply, demand, and competitive forces—and its financial trajectory, including revenue trends, patent influences, and future projections. Professionals in pharmaceuticals and investment sectors will find actionable insights here to navigate an evolving market.

Overview of Trazodone Hydrochloride

Trazodone hydrochloride stands out for its dual therapeutic applications, balancing efficacy with a relatively favorable side-effect profile compared to older antidepressants. The drug modulates serotonin levels, offering relief for depression while serving as a sedative for sleep disorders. In 2023, global sales of trazodone and its generics exceeded $500 million, driven by rising mental health awareness and prescriptions in key markets like the United States and Europe.

The pharmaceutical industry classifies trazodone as a mature product, with production dominated by generic manufacturers since the original patent expired in 1995. Leading producers include Teva Pharmaceuticals and Mylan, which leverage cost-effective synthesis to maintain steady supply chains. Demand surges in regions with high stress-related disorders, such as North America, where annual prescriptions top 10 million, according to IQVIA data.

Regulatory bodies like the FDA and European Medicines Agency (EMA) enforce strict quality controls, ensuring bioavailability and safety. These oversight mechanisms prevent market disruptions, though occasional shortages—linked to raw material constraints—have occurred, as seen in 2022 amid global supply chain volatility.

Current Market Dynamics

Trazodone's market thrives on robust demand fueled by the global mental health crisis. The World Health Organization reports that depression affects over 264 million people worldwide, propelling antidepressant consumption. In the U.S., trazodone captures a 5-7% share of the antidepressant market, valued at $15 billion in 2023, per Statista insights. Its affordability, with generic prices averaging $0.10 per tablet, broadens access, particularly in emerging economies like India and Brazil.

Competition intensifies from alternatives such as selective serotonin reuptake inhibitors (SSRIs) like sertraline and fluoxetine, which hold larger market shares due to fewer side effects. However, trazodone differentiates itself through its sedative properties, attracting patients with comorbid insomnia. Market entry barriers remain low for generics, yet branded versions from companies like Angelini Pharma persist in niche segments.

Supply dynamics hinge on active pharmaceutical ingredient (API) sourcing, primarily from Asia. China and India dominate production, accounting for 60% of global API supply, as noted in a 2023 report by the International Pharmaceutical Federation. This dependency introduces risks, including geopolitical tensions that could disrupt exports. Conversely, demand elasticity allows price adjustments; a 10% price drop in 2022 correlated with a 15% volume increase in the U.S., illustrating consumer sensitivity.

Regulatory shifts further shape dynamics. The FDA's 2021 guidance on generic drug equivalence has streamlined approvals, fostering competition and capping prices. In Europe, the EMA's focus on pharmacovigilance has led to updated labeling for trazodone, emphasizing cardiac risks, which slightly curbed prescriptions in 2023 but spurred innovation in safer formulations.

Economic factors, such as inflation and healthcare spending cuts, modulate growth. The drug's market expanded 4% year-over-year in 2023, outpacing the broader pharmaceutical sector's 2% growth, driven by telemedicine's rise, which boosted prescriptions during the COVID-19 era.

Financial Trajectory

Trazodone's financial path reflects a transition from patented innovation to generic commoditization. Post-patent expiration in 1995, revenues plummeted for original holders, but the drug's generics generated steady cash flows for manufacturers. In 2023, global revenues reached approximately $550 million, with Teva Pharmaceuticals reporting $150 million from trazodone sales alone, based on company filings.

Historically, peak revenues occurred in the late 1980s and early 1990s, exceeding $200 million annually for Mead Johnson. Today, financial performance stabilizes around low single-digit growth, supported by volume increases rather than price hikes. IQVIA's 2023 market analysis projects a compound annual growth rate (CAGR) of 3% through 2028, propelled by aging populations and mental health initiatives.

Key financial metrics reveal profitability. Gross margins for generic producers hover at 40-50%, thanks to efficient manufacturing. However, pricing pressures erode these figures; in the U.S., the average wholesale price fell 8% from 2022 to 2023, per Medi-Span data, as more competitors entered. Investment in R&D for extended-release formulations, like those pursued by Apotex, aims to recapture margins, with one such product launching in 2024.

The trajectory faces headwinds from patent cliffs and biosimilar threats, though trazodone's generic status limits this. Future revenues hinge on market expansion in Asia-Pacific, where growth could reach 5% annually, according to a Frost & Sullivan report. Strategic acquisitions, such as Teva's 2022 purchase of a trazodone production facility, signal confidence in sustained demand.

Wall Street analysts forecast modest returns, with trazodone-linked stocks like Teva's showing 10% gains in 2023 amid broader pharma rebounds. Investors should monitor reimbursement policies; in 2024, U.S. Medicare adjustments could reduce payouts by 5%, impacting net revenues.

Patent Landscape and Regulatory Influences

Although trazodone's core patent expired decades ago, secondary patents on formulations and delivery methods extend competitive edges. For instance, the FDA approved a new extended-release version in 2019, protected until 2029, as per USPTO records. This innovation shields manufacturers from pure commoditization, enabling premium pricing for advanced products.

Regulatory approvals drive financial shifts. The EMA's 2023 endorsement of trazodone for pediatric use in certain EU countries expanded market access, potentially adding $50 million in annual revenues. Conversely, FDA warnings on rare side effects in 2022 prompted labeling changes, temporarily denting sales by 2%.

Globally, intellectual property enforcement varies. In markets like China, weak patent protections increase counterfeiting risks, eroding authentic product revenues. Companies counter this through partnerships, such as Pfizer's collaboration with local firms to safeguard supply chains.

Future Outlook

Looking ahead, trazodone's market will evolve with demographic and technological trends. By 2030, the global antidepressant market could hit $25 billion, with trazodone maintaining a steady 5% share, per Grand View Research projections. Emerging markets in Latin America and Africa offer growth opportunities, as urbanization fuels mental health needs.

Advancements in personalized medicine may integrate trazodone into combination therapies, boosting demand. Financially, revenues could rise 4-6% annually if supply chains stabilize and new formulations gain traction. However, climate-related disruptions to API production pose risks, potentially causing shortages that cut growth by 2-3%.

Stakeholders must adapt to policy changes, such as the WHO's push for affordable generics, which could compress margins. Overall, trazodone's trajectory points to resilience, with strategic investments in sustainability and digital health enhancing long-term viability.

Key Takeaways

  • Trazodone hydrochloride sustains demand through its affordability and versatility in treating depression and insomnia, driving steady market growth amid global mental health trends.
  • Financial performance remains robust for generic producers, with projected CAGR of 3% through 2028, though pricing pressures and regulatory hurdles could limit gains.
  • Patent extensions on new formulations provide temporary competitive advantages, but reliance on Asian supply chains introduces volatility.
  • Investors should prioritize markets with expanding healthcare access, while monitoring regulatory updates to mitigate risks.
  • The drug's future hinges on innovation and adaptation to demographic shifts, ensuring its role in a growing pharmaceutical sector.

Frequently Asked Questions

  1. What factors primarily drive demand for trazodone hydrochloride?
    Demand stems from increasing depression rates and its off-label use for insomnia, with prescriptions rising in response to global mental health initiatives.

  2. How has the expiration of trazodone's original patent affected its financials?
    The 1995 patent expiration shifted the drug to generic status, reducing prices and revenues for original manufacturers but enabling broader market penetration and steady income for generics producers.

  3. What competitive threats does trazodone face in the antidepressant market?
    It competes with SSRIs like sertraline, which offer fewer side effects, though trazodone's sedative benefits maintain its niche appeal.

  4. How might regulatory changes impact trazodone's future trajectory?
    Stricter FDA and EMA guidelines on side effects could alter labeling and prescriptions, potentially slowing growth but encouraging safer innovations.

  5. What investment opportunities exist in trazodone's market?
    Opportunities lie in emerging markets and advanced formulations, where companies like Teva are expanding to capitalize on rising demand.

Sources

  1. IQVIA Institute for Human Data Science. (2023). Global Use of Medicines 2023 Outlook. Retrieved from IQVIA reports.
  2. Statista. (2023). Antidepressant Market Size and Forecast. Retrieved from Statista database.
  3. Frost & Sullivan. (2023). Pharmaceutical Market Insights Report. Retrieved from Frost & Sullivan publications.
  4. U.S. Food and Drug Administration (FDA). (2019). Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from FDA website.
  5. World Health Organization (WHO). (2023). Depression and Other Common Mental Disorders: Global Health Estimates. Retrieved from WHO reports.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.